6,800,000 Shares HALOZYME THERAPEUTICS, INC. Common Stock ($0.001 par value) UNDERWRITING AGREEMENTUnderwriting Agreement • February 10th, 2012 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to sell 6,800,000 shares (the “Firm Stock”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company proposes to grant to Barclays Capital Inc., as sole underwriter (the “Underwriter”), an option to purchase up to an aggregate of 1,020,000 additional shares of the Common Stock on the terms set forth in Section 2 (the “Option Stock”). The Firm Stock and the Option Stock, if purchased, are hereinafter collectively called the “Stock.” This is to confirm the agreement (this “Agreement”) concerning the purchase of the Stock from the Company by the Underwriter.
